Target intelligence / Profile preview

Proteasomal ubiquitin receptor ADRM1 (Rpn13)

Target
Rpn13
Molecular classification
Ubiquitin receptor, Proteasome subunit, Regulatory particle subunit (19S), Non-ATPase subunit
01

Overview

Proteasomal ubiquitin receptor ADRM1 (Rpn13) is a non-ATPase subunit of the 19S regulatory particle in the 26S proteasome, essential for intracellular protein degradation. Rpn13 functions as a ubiquitin receptor, recognizing and binding ubiquitinated substrates and facilitating their recruitment and processing by the proteasome. It contains a conserved N-terminal Pru domain for ubiquitin binding and interacts with other proteasomal components, notably the deubiquitinating enzyme UCHL5/Uch37. Rpn13 is critical for protein homeostasis and targeted degradation of misfolded or regulatory proteins, and its dysfunction or inhibition is linked to diseases such as cancer. Rpn13 is a validated therapeutic target with small molecule inhibitors in development for oncology indications.

Other names
ADRM1ARM-1ARM1GP110adhesion regulating molecule 1PSMD16ADRM1 26S proteasome ubiquitin receptor26S Proteasome regulatory subunit Rpn13
02

Mechanism of action

Inhibition of Rpn13 prevents docking of ubiquitinated proteins for degradation Inhibitors may cause accumulation of misfolded/damaged proteins, leading to cellular stress and apoptosis, especially in cancer cells

03

Biological functions

Recognition and binding of ubiquitinated proteinsDocking of ubiquitinated substrates to the proteasomeAssembly and stabilization of the 19S proteasome base subcomplexPromotion of protein degradation via the ubiquitin-proteasome pathwayCoupling of substrate recognition and deubiquitination
04

Disease associations

Cancer (ADRM1 gene expression is induced by gamma interferon in some cancer cells; the ubiquitin-proteasome pathway is implicated widely in cancer biology)Other diseases linked to proteasome function and protein homeostasis
05

Safety considerations

Potential for cellular toxicity due to broad role in proteasome function and general protein degradationPossible off-target effects due to inhibition of essential protein clearance pathways
06

Interacting drugs

RA190 (a small molecule inhibitor targeting Rpn13, known to induce proteotoxic stress and apoptosis in cancer cells)

1 more in the full profile.

07

Biomarkers

ADRM1 expression levels (potential biomarker for some cancers)Ubiquitin-conjugated protein levels (as indirect markers of proteasome inhibition)

Beyond the preview

Go deeper on Proteasomal ubiquitin receptor ADRM1 (Rpn13).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Proteasomal ubiquitin receptor ADRM1 (Rpn13).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call